On Air Now

Upcoming Shows

Program Schedule »

Tune in to Listen

650 AM Hibbing, Minnesota

Weather

Current Conditions(Hibbing,MN 55746)

More Weather »
34° Feels Like: 23°
Wind: WSW 20 mph Past 24 hrs - Precip: 0.2”
Current Radar for Zip

Today

Rain/Wind 52°

Tonight

Partly Cloudy 33°

Tomorrow

Partly Cloudy 63°

Alerts

FDA approves Bayer drug for rare gastrointestinal tract cancer

A general view shows the annual general meeting of Bayer AG in Cologne April 27, 2012. Bayer's Chief Executive Marijn Dekkers reiterated the
A general view shows the annual general meeting of Bayer AG in Cologne April 27, 2012. Bayer's Chief Executive Marijn Dekkers reiterated the

WASHINGTON (Reuters) - The U.S. Food and Drug Administration said on Monday it has approved Bayer AG's drug Stivarga for the treatment of a rare type of gastrointestinal tract cancer.

Stivarga is already approved to treat colon cancer that has progressed after prior treatment or that has spread to other parts of the body. Bayer will now also be able to market the drug as a treatment for gastrointestinal stromal tumors (GIST).

Stivarga, known chemically as regorafenib, was tested in 199 patients with GIST that could not be surgically removed and had progressed after treatment with other therapies. Patients taking Stivarga had a delay in tumor growth progression that was on average 3.9 months later than patients given a placebo.

(Reporting By Toni Clarke in Washington; editing by John Wallace)

Comments